Harbin Medisan Pharmaceutical Co., Ltd.

Symbol: 002900.SZ

SHZ

10.31

CNY

Market price today

  • 62.4601

    P/E Ratio

  • 1.8348

    PEG Ratio

  • 3.19B

    MRK Cap

  • 0.01%

    DIV Yield

Harbin Medisan Pharmaceutical Co., Ltd. (002900-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Harbin Medisan Pharmaceutical Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

balance-sheet.row.cash-and-short-term-investments

01048.91293.91111.5
1022.2
1168.2
556.6
354.7
128.8
80.9
93.2
85.9
80.2

balance-sheet.row.short-term-investments

057.891.3581.7
360.8
696.7
104.9
0
-4.1
0
0
-3.5
0

balance-sheet.row.net-receivables

0150.6164.1149.6
204.7
256.1
249.8
192.2
109.6
97.4
108.9
140.8
135.2

balance-sheet.row.inventory

0208.8161.2156.5
186.5
214.3
183.9
147.7
89.1
104.5
105.4
100.7
98.4

balance-sheet.row.other-current-assets

028.24.59.5
26.7
46.9
654.9
664.4
12.2
10
-2.4
-19.4
-16.1

balance-sheet.row.total-current-assets

01436.41623.71427.2
1440.2
1685.6
1645.2
1359
339.8
292.8
305.1
308.1
297.8

balance-sheet.row.property-plant-equipment-net

01081.6882.4925.3
867.3
806.7
725.7
721.7
722.6
671.6
571
456.5
332.3

balance-sheet.row.goodwill

01.30.59.4
9.4
9.4
9.4
9.4
9.4
9.4
10.8
10.8
10.3

balance-sheet.row.intangible-assets

0141.271.762.5
66.4
70.1
72.6
50.6
51.8
52.7
53.7
54.6
62.6

balance-sheet.row.goodwill-and-intangible-assets

0142.572.271.9
75.9
79.5
82
60.1
61.2
62.1
64.5
65.4
72.9

balance-sheet.row.long-term-investments

0651.2555.622.8
-345.9
-673.3
-72
0
8.1
0
0
7.6
3.2

balance-sheet.row.tax-assets

023.123.825.8
23.9
21.1
21.6
19.9
20.5
20.6
23.6
21
13.7

balance-sheet.row.other-non-current-assets

0108.1119.1592.4
421.4
752.6
111.1
23
14
5.8
6.2
-0.8
-0.9

balance-sheet.row.total-non-current-assets

02006.51653.11638.3
1042.6
986.5
868.3
824.8
826.4
760.1
665.4
549.7
421.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

034433276.83065.5
2482.8
2672.1
2513.6
2183.7
1166.2
1052.9
970.5
857.8
719

balance-sheet.row.account-payables

0182.1120.8105.2
90
96.4
76.8
78
97
99.3
128.4
125.5
109.4

balance-sheet.row.short-term-debt

0480.2233.8274.8
269.8
180
58
0
106
90
107
127
72

balance-sheet.row.tax-payables

03.112.211.2
10.8
31.9
19.1
46.1
27
13.8
8.8
42.6
33

balance-sheet.row.long-term-debt-total

0238.2422.9212.9
10.9
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

07983.989
88.7
84.9
90.3
82.2
86.1
89.1
88.8
68.1
53.5

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

07.9188.32.5
2.1
96.7
293.3
188.6
20.7
18
13.6
27.3
35.6

balance-sheet.row.total-non-current-liabilities

0449.7627.1412.4
102.3
97.1
96.6
82.2
86.1
89.1
88.8
68.1
53.5

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

08.35.18
10.9
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

01294.81224.8949
691.2
820.4
543.8
348.8
358
325
361.3
492.6
376.3

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0316.4316.6316.6
316.6
316.6
316.6
211.1
158.3
158.3
158.3
150
10.4

balance-sheet.row.retained-earnings

0612.9570.7639.6
341.2
411.1
463
391.9
306.7
244.3
142.8
11.3
310.3

balance-sheet.row.accumulated-other-comprehensive-income-loss

00162.5192.3
164.5
152.1
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

01211.2990.9952.9
952.9
952.9
1167.9
1232
343.2
325.3
308
203.8
15.2

balance-sheet.row.total-stockholders-equity

02140.52040.72101.4
1775.3
1832.7
1947.5
1834.9
808.2
728
609.2
365.1
335.9

balance-sheet.row.total-liabilities-and-stockholders-equity

034433276.83065.5
2482.8
2672.1
2513.6
2183.7
1166.2
1052.9
970.5
857.8
719

balance-sheet.row.minority-interest

07.711.315
16.3
19
22.3
0
0
0
0
0
6.9

balance-sheet.row.total-equity

02148.220522116.5
1791.6
1851.7
1969.8
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-

Total Investments

0709646.9604.5
14.9
23.4
32.9
20
4.1
4.1
4.1
4.1
3.2

balance-sheet.row.total-debt

0718.4656.7487.7
269.8
180
58
0
106
90
107
127
72

balance-sheet.row.net-debt

0-272.8-545.9-42.2
-391.7
-291.5
-393.7
-354.7
-22.8
9.1
13.8
41.1
-8.2

Cash Flow Statement

The financial landscape of Harbin Medisan Pharmaceutical Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

cash-flows.row.net-income

026.5349.726.6
173.9
204.4
181.1
175.2
166.3
147
104.4
82.7

cash-flows.row.depreciation-and-amortization

0106.699.179.9
79
73.8
68.8
57.8
47.2
36.2
0
0

cash-flows.row.deferred-income-tax

011.795-1.4
7.2
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0-11.7-951.4
-7.2
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

049.5107.4-160.1
76.1
41.6
-9.2
-13.6
-10.2
-74.1
0
0

cash-flows.row.account-receivables

0-1049.649.1
-59
0
0
0
0
0
0
0

cash-flows.row.inventory

00.626.531.9
-33.6
-39
-60
13.7
0.9
-4.6
0
0

cash-flows.row.account-payables

047.2-63.7-239.6
161.6
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

011.795-1.4
7.2
80.7
50.8
-27.3
-11.1
-69.4
0
0

cash-flows.row.other-non-cash-items

0-37.9-568.849
-8.8
-27.4
-17.2
11.8
-2.4
7.2
-104.4
-82.7

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-89.2-73.9-145.9
-198.6
-78.4
-104.9
-93.9
-141.7
-145.8
-154.1
-91

cash-flows.row.acquisitions-net

00.311.6146.4
199.4
0
105
0
-0.5
8.4
-0.5
-5.7

cash-flows.row.purchases-of-investments

0-72-1113.7-1091
-2271
-2482.1
-655
-14
0
0
-19.9
-40

cash-flows.row.sales-maturities-of-investments

0580.2901.91437.6
2340.9
2399.5
34.6
0
0
0
0.1
40.1

cash-flows.row.other-investing-activites

00-4.1-145.9
-198.6
0.6
-104.9
0.1
0
1.3
-0.1
0.1

cash-flows.row.net-cash-used-for-investing-activites

0419.3-278.2201.3
-128
-160.5
-725.3
-107.8
-142.2
-136.1
-174.5
-96.5

cash-flows.row.debt-repayment

0-270.2-269.5-230
-58
-30
-207
-90
-157
-207
-112
-96

cash-flows.row.common-stock-issued

0000
85.8
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
-85.8
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-109.3-34.3-95.8
-209
-107.5
-92.4
-91.4
-54
-52.5
-42
-4.7

cash-flows.row.other-financing-activites

0272.4260.1323.2
88.9
109.8
1020.7
115
141.9
290.1
161.3
115.6

cash-flows.row.net-cash-used-provided-by-financing-activities

0-107.1-43.7-2.6
-178.1
-27.6
721.3
-66.4
-69.1
30.6
7.3
15

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

0456.8-334.5194.2
14.1
104.4
219.5
57
-10.4
10.8
-0.1
41.7

cash-flows.row.cash-at-end-of-period

0782.3325.5660
465.7
451.7
347.3
127.8
70.9
81.3
70.5
70.5

cash-flows.row.cash-at-beginning-of-period

0325.5660465.7
451.7
347.3
127.8
70.9
81.3
70.5
70.5
28.9

cash-flows.row.operating-cash-flow

0144.6-12.5-4.5
320.1
292.5
223.5
231.2
200.8
116.3
0
0

cash-flows.row.capital-expenditure

0-89.2-73.9-145.9
-198.6
-78.4
-104.9
-93.9
-141.7
-145.8
-154.1
-91

cash-flows.row.free-cash-flow

055.4-86.5-150.4
121.5
214
118.5
137.3
59.1
-29.5
-154.1
-91

Income Statement Row

Harbin Medisan Pharmaceutical Co., Ltd.'s revenue saw a change of NaN% compared with the previous period. The gross profit of 002900.SZ is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

income-statement-row.row.total-revenue

01186.81028.4945.8
1338.9
2102.1
2172.5
1148.8
760.9
722
681.5
601.2
491.2

income-statement-row.row.cost-of-revenue

0476.4365.6309.4
491.3
509.9
352
296.7
290
275.9
287.4
280.7
268.5

income-statement-row.row.gross-profit

0710.4662.8636.4
847.6
1592.1
1820.5
852.1
470.8
446.2
394.1
320.5
222.6

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

02.4110.546.5
-11.1
27.2
-1.9
0.3
17.4
12
20
2.1
-6.6

income-statement-row.row.operating-expenses

0693.4679.6765.2
786.5
1384.1
1604.9
619.5
264.5
263.4
226.3
174.1
108.5

income-statement-row.row.cost-and-expenses

01169.71045.11074.6
1277.8
1894
1956.9
916.2
554.5
539.3
513.8
454.9
377

income-statement-row.row.interest-income

027.928.311.8
10
8.5
14.9
1.7
0.7
0.6
0.7
0
0

income-statement-row.row.interest-expense

022.922.613.8
9.3
6.5
2
5
4.6
6.5
8
6.1
4.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

02.4-17.5-1.9
-51.1
-0.6
33.5
20.4
2.8
15.3
6.7
-24.2
-19.5

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

02.4110.546.5
-11.1
27.2
-1.9
0.3
17.4
12
20
2.1
-6.6

income-statement-row.row.total-operating-expenses

02.4-17.5-1.9
-51.1
-0.6
33.5
20.4
2.8
15.3
6.7
-24.2
-19.5

income-statement-row.row.interest-expense

022.922.613.8
9.3
6.5
2
5
4.6
6.5
8
6.1
4.3

income-statement-row.row.depreciation-and-amortization

0108.7106.6122.9
79.9
75.8
73.8
68.8
57.8
47.2
36.2
45.2
19.6

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

07957.6454.8
84.2
228.8
251
252.7
197.8
186.9
163.6
121.4
103

income-statement-row.row.income-before-tax

081.440.1452.9
33.2
228.2
249.1
253
209.1
198
174.5
122.2
94.6

income-statement-row.row.income-tax-expense

011.313.6103.2
6.5
54.4
44.7
72
33.9
31.7
27.5
17.9
14.3

income-statement-row.row.net-income

073.730.2351
29.3
177.2
205.8
181.1
175.2
166.3
147
104.4
82.7

Frequently Asked Question

What is Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) total assets?

Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) total assets is 3442984089.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.582.

What is company free cash flow?

The free cash flow is -1.022.

What is enterprise net profit margin?

The net profit margin is 0.049.

What is firm total revenue?

The total revenue is 0.026.

What is Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) net profit (net income)?

The net profit (net income) is 73663110.000.

What is firm total debt?

The total debt is 718376453.000.

What is operating expences number?

The operating expences are 693357200.000.

What is company cash figure?

Enretprise cash is 0.000.